Insulet raises annual outlook as international sales accelerate
The medical device maker reported first-quarter revenue of $761.7 million, a 33.9% increase from a year earlier.
Insulet (PODD) reported first-quarter revenue that exceeded the high end of its own guidance. The medical device maker saw growth driven largely by the expansion of its tubeless insulin delivery systems across global markets.
Total revenue for the quarter rose 33.9% to $761.7 million. On a constant currency basis, the increase was 30.1%, surpassing the company's previously projected range of 25% to 27%. Adjusted operating margin expanded 110 basis points from the prior year to 17.5% of revenue.
International Omnipod revenue grew 59.4% year-over-year. This growth outpaced the 28.3% increase seen in U.S. Omnipod revenue during the same period. In constant currency terms, international growth stood at 45.2%.
Other business lines saw a sharp contraction. Drug Delivery revenue fell 77.9% to $3.3 million, down from $14.9 million in the first quarter of 2025.
Insulet raised its full-year 2026 total company revenue growth guidance in constant currency to 21%-23%, up from a previous range of 20%-22%. The company also increased its full-year international Omnipod revenue guidance to 26%-28%, compared to the prior forecast of 24%-26%.
The results follow a period of manufacturing challenges. In May 2026, the company initiated a voluntary medical device correction for approximately 7 million Pods, representing roughly 8.5% of 2025 global production, due to an issue causing insulin under-delivery. This followed a March 12, 2026, correction that affected 1.5% of annual Omnipod 5 production.
Insulet repurchased 1.25 million shares of common stock during the first quarter. The company also appointed Jonathan J. Mazelsky to its Board of Directors, effective July 1, 2026.